$FDMT 8-K SEC Filings

Filed On	Filing
28 Sep 2026	8-K: Other Events On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular...
13 Aug 2026	8-K: Results of Operations and Financial Condition
20 Jul 2026	8-K: Other Events
29 Jun 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
22 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
07 May 2026	8-K: Results of Operations and Financial Condition
30 Mar 2026	8-K: Departure/Election of Directors or Officers; Compensation
18 Mar 2026	8-K: Results of Operations and Financial Condition
26 Jan 2026	8-K: Unregistered Sales of Equity Securities
07 Jan 2026	8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
10 Dec 2025	8-K: Other Events
17 Nov 2025	8-K: Departure/Election of Directors or Officers; Compensation
10 Nov 2025	8-K: Results of Operations and Financial Condition
07 Nov 2025	8-K: Other Events
06 Nov 2025	8-K: Results of Operations and Financial Condition; Other Events
31 Oct 2025	8-K: Entry into a Material Definitive Agreement
02 Oct 2025	8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year
11 Aug 2025	8-K: Results of Operations and Financial Condition
02 Jul 2025	8-K: Departure/Election of Directors or Officers; Compensation; Other Events
20 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders

Comments